Evidence map›Paper›PMID 25459179›Full record

ReviewHematology/oncology clinics of North America2014

Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?

Fabienne McClanahan, John Gribben

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Fabienne McClanahanCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK; Division of Molecular Genetics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, Heidelberg 69120, Germany.
John GribbenCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M6BQ, UK. Electronic address: j.gribben@qmul.ac.uk.
Queen Mary University of London · GB

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Novel pharmacologic agents in CLLP20CA081534 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI KIPPS, THOMAS J. · 1999 to 1999
–
NCI NIH HHS P01 CA081534NCI NIH HHS P20 CA081534
6 · The paper itself

Abstract

Allogeneic stem cell transplantation (HSCT) offers the only potentially curative approach in chronic lymphocytic leukemia (CLL). However, this applies only to a minority of patients, and is associated with significant treatment-related mortality and morbidity. HSCT must therefore always be considered in view of other, potentially less toxic therapies. Several new agents demonstrate impressive and durable responses in high-risk patients who might be candidates for HSCT. Therefore the choice of HSCT versus a novel agent is one that must be gauged on a patient-by-patient basis; this will change as data mature on the use of these novel agents in CLL.

Indexed as

Hematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellMolecular Targeted TherapyRisk FactorsSurvival AnalysisTransplantation, HomologousTreatment OutcomeAllogeneic hematopoietic stem cell transplantationChronic lymphocytic leukemiaGvHDGvLHigh-risk patientsNovel substances

Identifiers

PMID25459179
PMCPMC4254558
OpenAlexW29792688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.